{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:32:37Z","timestamp":1792704757031,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The impact of amino acids on tumor immunotherapy is gradually being uncovered. In this study, we screened various essential and non-essential amino acids and found that methionine enhances mRNA methylation and reduced the activation of Type I interferon pathway in bladder cancer. Through RNA sequencing, point mutations, MB49 mouse tumor models, and single-cell RNA sequencing, we demonstrated that high methionine levels elevate the expression of m\n                    <jats:sup>6<\/jats:sup>\n                    A reader YTHDF1, promoting the degradation of RIG-I, thereby inhibiting the RIG-I\/MAVS-mediated IFN-I pathway and reducing the efficacy of tumor immunotherapy. Additionally, immunoprecipitation and mass spectrometry revealed that YTHDF1 binds to the eukaryotic translation initiation factor eIF5B, which acts on PD-L1 mRNA to enhance its translation and promote immune evasion. By intravesical administration of oncolytic bacteria VNP20009, we effectively depleted methionine locally, significantly prolonging mouse survival and enhancing immune cell infiltration and differentiation within tumors. Multiplex immunofluorescence assays in bladder cancer immunotherapy patients confirmed our findings. Our research elucidates two mechanisms by which methionine inhibits bladder cancer immunotherapy and proposes a targeted methionine depletion strategy that advances research while minimizing nutritional impact on patients.\n                  <\/jats:p>","DOI":"10.1038\/s41418-024-01434-y","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T11:57:42Z","timestamp":1734091062000},"page":"776-791","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Methionine-driven YTHDF1 expression facilitates bladder cancer progression by attenuating RIG-I-modulated immune responses and enhancing the eIF5B-PD-L1 axis"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3998-1198","authenticated-orcid":false,"given":"Anze","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8038-4742","authenticated-orcid":false,"given":"Liangmin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanyu","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3737-3535","authenticated-orcid":false,"given":"Yinghan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zifang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taowei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8889-5122","authenticated-orcid":false,"given":"Zhenhua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongbing","family":"Zu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8701-6405","authenticated-orcid":false,"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0734-2884","authenticated-orcid":false,"given":"Junxing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5706-0990","authenticated-orcid":false,"given":"Junhang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,13]]},"reference":[{"key":"1434_CR1","doi-asserted-by":"crossref","first-page":"e007230","DOI":"10.1136\/jitc-2023-007230","volume":"11","author":"A Yu","year":"2023","unstructured":"Yu A, Hu J, Fu L, Huang G, Deng D, Zhang M, et al. Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8(+) T cell infiltration and functional transition. J Immunother Cancer. 2023;11:e007230.","journal-title":"J Immunother Cancer"},{"key":"1434_CR2","doi-asserted-by":"crossref","first-page":"e076743","DOI":"10.1136\/bmj-2023-076743","volume":"384","author":"A Lopez-Beltran","year":"2024","unstructured":"Lopez-Beltran A, Cookson MS, Guercio BJ, Cheng L. Advances in diagnosis and treatment of bladder cancer. BMJ 2024;384:e076743.","journal-title":"BMJ"},{"key":"1434_CR3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S1470-2045(23)00633-2","volume":"25","author":"AO Siefker-Radtke","year":"2024","unstructured":"Siefker-Radtke AO, Desai M. Evolution of front-line immunotherapy for metastatic urothelial cancer. Lancet Oncol. 2024;25:2\u20133.","journal-title":"Lancet Oncol"},{"key":"1434_CR4","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2023.06.017","volume":"84","author":"M Koti","year":"2023","unstructured":"Koti M, Robert Siemens D. A step closer to predicting progression after bacillus calmette-gu\u00e9rin immunotherapy in high-risk non-muscle-invasive bladder cancer. Eur Urol. 2023;84:447\u20138.","journal-title":"Eur Urol"},{"key":"1434_CR5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.eururo.2022.11.008","volume":"83","author":"J Griffin","year":"2023","unstructured":"Griffin J. TIME for a change? Multimarker assessment of the tumour immune microenvironment and metastatic site biopsy to improve immunotherapy response prediction in muscle-invasive bladder cancer. Eur Urol. 2023;83:143\u20134.","journal-title":"Eur Urol"},{"key":"1434_CR6","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1001\/jamaoncol.2023.2174","volume":"9","author":"A Necchi","year":"2023","unstructured":"Necchi A, Faltas BM, Slovin SF, Meeks JJ, Pal SK, Schwartz LH, et al. Immunotherapy in the treatment of localized genitourinary cancers. JAMA Oncol. 2023;9:1447\u201354.","journal-title":"JAMA Oncol"},{"key":"1434_CR7","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1001\/jamaoncol.2023.3304","volume":"9","author":"TJ Hwang","year":"2023","unstructured":"Hwang TJ, Davies BJ, Preston MA. Advancing patient-centered outcomes and equity in clinical trials for BCG-unresponsive nonmuscle invasive bladder cancer. JAMA Oncol. 2023;9:1491\u20132.","journal-title":"JAMA Oncol"},{"key":"1434_CR8","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.eururo.2022.08.032","volume":"82","author":"D Hayne","year":"2022","unstructured":"Hayne D, Redfern A. The evolving role of locally delivered checkpoint inhibitors in non-muscle-invasive bladder cancer. Eur Urol. 2022;82:611\u20132.","journal-title":"Eur Urol"},{"key":"1434_CR9","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.trecan.2022.03.007","volume":"8","author":"D Ranti","year":"2022","unstructured":"Ranti D, Bieber C, Wang YS, Sfakianos JP, Horowitz A. Natural killer cells: unlocking new treatments for bladder cancer. Trends Cancer. 2022;8:698\u2013710.","journal-title":"Trends Cancer"},{"key":"1434_CR10","doi-asserted-by":"crossref","first-page":"e2209379","DOI":"10.1002\/adma.202209379","volume":"35","author":"W Su","year":"2023","unstructured":"Su W, Qiu W, Li SJ, Wang S, Xie J, Yang QC, et al. A dual-responsive STAT3 inhibitor nanoprodrug combined with oncolytic virus elicits synergistic antitumor immune responses by igniting pyroptosis. Adv Mater. 2023;35:e2209379.","journal-title":"Adv Mater"},{"key":"1434_CR11","doi-asserted-by":"crossref","unstructured":"Moreo E, Uranga S, Pic\u00f3 A, G\u00f3mez AB, Nardelli-Haefliger D, Del Fresno C, et al. Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors. J Immunother Cancer. 2022;10:e004325.","DOI":"10.1136\/jitc-2021-004325"},{"key":"1434_CR12","first-page":"4234","volume":"10","author":"J Fu","year":"2020","unstructured":"Fu J, Yu A, Xiao X, Tang J, Zu X, Chen W, et al. CD4(+) T cell exhaustion leads to adoptive transfer therapy failure which can be prevented by immune checkpoint blockade. Am J Cancer Res. 2020;10:4234\u201350.","journal-title":"Am J Cancer Res"},{"key":"1434_CR13","doi-asserted-by":"crossref","first-page":"100210","DOI":"10.1016\/j.labinv.2023.100210","volume":"103","author":"A Yu","year":"2023","unstructured":"Yu A, Xu X, Pang Y, Li M, Luo J, Wang J, et al. PD-L1 expression is linked to tumor-infiltrating T-cell exhaustion and adverse pathological behavior in pheochromocytoma\/paraganglioma. Lab Investig. 2023;103:100210.","journal-title":"Lab Investig"},{"key":"1434_CR14","doi-asserted-by":"crossref","first-page":"0271","DOI":"10.34133\/research.0271","volume":"6","author":"A Yu","year":"2023","unstructured":"Yu A, Fu J, Yin Z, Yan H, Xiao X, Zou D, et al. Continuous expression of interferon regulatory factor 4 sustains CD8(+) T cell Immunity against Tumor. Research. 2023;6:0271.","journal-title":"Research"},{"key":"1434_CR15","doi-asserted-by":"crossref","first-page":"e111961","DOI":"10.15252\/embj.2022111961","volume":"42","author":"C Taffoni","year":"2023","unstructured":"Taffoni C, Marines J, Chamma H, Guha S, Saccas M, Bouzid A, et al. DNA damage repair kinase DNA-PK and cGAS synergize to induce cancer-related inflammation in glioblastoma. EMBO J. 2023;42:e111961.","journal-title":"EMBO J"},{"key":"1434_CR16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13045-023-01405-9","volume":"16","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Zhang H, Wang J, Chen J, Guo Z, Liu Y, et al. Exploiting RIG-I-like receptor pathway for cancer immunotherapy. J Hematol Oncol. 2023;16:8.","journal-title":"J Hematol Oncol"},{"key":"1434_CR17","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41577-022-00789-y","volume":"22","author":"Y Bordon","year":"2022","unstructured":"Bordon Y. Disturbance of cytoskeleton primes RIG-I-like receptors. Nat Rev Immunol. 2022;22:654\u20135.","journal-title":"Nat Rev Immunol"},{"key":"1434_CR18","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13045-022-01381-6","volume":"15","author":"Z Li","year":"2022","unstructured":"Li Z, Zhou Y, Jia K, Yang Y, Zhang L, Wang S, et al. JMJD4-demethylated RIG-I prevents hepatic steatosis and carcinogenesis. J Hematol Oncol. 2022;15:161.","journal-title":"J Hematol Oncol"},{"key":"1434_CR19","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1182\/blood.2021013048","volume":"139","author":"Q Lou","year":"2022","unstructured":"Lou Q, Jiang K, Xu Q, Yuan L, Xie S, Pan Y, et al. The RIG-I-NRF2 axis regulates the mesenchymal stromal niche for bone marrow transplantation. Blood. 2022;139:3204\u201321.","journal-title":"Blood."},{"key":"1434_CR20","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1158\/2159-8290.CD-23-0486","volume":"14","author":"T Murayama","year":"2024","unstructured":"Murayama T, Nakayama J, Jiang X, Miyata K, Morris AD, Cai KQ, et al. Targeting DHX9 triggers tumor-intrinsic interferon response and replication stress in small cell lung cancer. Cancer Discov. 2024;14:468\u201391.","journal-title":"Cancer Discov."},{"key":"1434_CR21","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1158\/2159-8290.CD-23-1523","volume":"14","author":"KB Chiappinelli","year":"2024","unstructured":"Chiappinelli KB. Targeting the DHX9 RNA helicase to induce antitumor immunity in small-cell lung cancer. Cancer Discov. 2024;14:389\u201391.","journal-title":"Cancer Discov."},{"key":"1434_CR22","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1158\/2159-8290.CD-22-0733","volume":"12","author":"S Guil","year":"2022","unstructured":"Guil S, Esteller M. PRC2 loss and dnmt inhibition boost viral mimicry in cancer. Cancer Discov. 2022;12:2020\u20132.","journal-title":"Cancer Discov."},{"key":"1434_CR23","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1001\/jama.2023.19897","volume":"330","author":"A Elmaleh-Sachs","year":"2023","unstructured":"Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M. Obesity management in adults: a review. JAMA 2023;330:2000\u201315.","journal-title":"JAMA"},{"key":"1434_CR24","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12986-020-00439-x","volume":"17","author":"JS Kang","year":"2020","unstructured":"Kang JS. Dietary restriction of amino acids for cancer therapy. Nutr Metab. 2020;17:20.","journal-title":"Nutr Metab"},{"key":"1434_CR25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s43018-023-00671-3","volume":"5","author":"F Li","year":"2024","unstructured":"Li F, Liu P, Mi W, Li L, Anderson NM, Lesner NP, et al. Blocking methionine catabolism induces senescence and confers vulnerability to GSK3 inhibition in liver cancer. Nat Cancer. 2024;5:131\u201346.","journal-title":"Nat Cancer."},{"key":"1434_CR26","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/cac2.12492","volume":"43","author":"W Lu","year":"2023","unstructured":"Lu W, Luo Y. Methionine restriction sensitizes cancer cells to immunotherapy. Cancer Commun. 2023;43:1267\u201370.","journal-title":"Cancer Commun"},{"key":"1434_CR27","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/s42255-023-00854-3","volume":"5","author":"M Ji","year":"2023","unstructured":"Ji M, Xu X, Xu Q, Hsiao YC, Martin C, Ukraintseva S, et al. Methionine restriction-induced sulfur deficiency impairs antitumour immunity partially through gut microbiota. Nat Metab. 2023;5:1526\u201343.","journal-title":"Nat Metab"},{"key":"1434_CR28","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.cmet.2022.08.008","volume":"34","author":"R Guo","year":"2022","unstructured":"Guo R, Liang JH, Zhang Y, Lutchenkov M, Li Z, Wang Y, et al. Methionine metabolism controls the B cell EBV epigenome and viral latency. Cell Metab. 2022;34:1280\u201397.e9.","journal-title":"Cell Metab"},{"key":"1434_CR29","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41586-020-2682-1","volume":"585","author":"Y Bian","year":"2020","unstructured":"Bian Y, Li W, Kremer DM, Sajjakulnukit P, Li S, Crespo J, et al. Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. Nature. 2020;585:277\u201382.","journal-title":"Nature."},{"key":"1434_CR30","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.trecan.2023.07.008","volume":"9","author":"F Wei","year":"2023","unstructured":"Wei F, Locasale JW. Methionine restriction and antitumor immunity. Trends Cancer. 2023;9:705\u20136.","journal-title":"Trends Cancer"},{"key":"1434_CR31","doi-asserted-by":"crossref","unstructured":"Morehead LC, Garg S, Wallis KF, Simoes CC, Siegel ER, Tackett AJ, et al. Increased response to immune checkpoint inhibitors with dietary methionine restriction in a colorectal cancer model. Cancers. 2023;15:4467.","DOI":"10.3390\/cancers15184467"},{"key":"1434_CR32","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1158\/0008-5472.CAN-21-1323","volume":"82","author":"Z Ni","year":"2022","unstructured":"Ni Z, Sun P, Zheng J, Wu M, Yang C, Cheng M, et al. JNK signaling promotes bladder cancer immune escape by regulating METTL3-mediated m6A modification of PD-L1 mRNA. Cancer Res. 2022;82:1789\u2013802.","journal-title":"Cancer Res"},{"key":"1434_CR33","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/1878-0261.13181","volume":"16","author":"C Guimar\u00e3es-Teixeira","year":"2022","unstructured":"Guimar\u00e3es-Teixeira C, Lobo J, Miranda-Gon\u00e7alves V, Barros-Silva D, Martins-Lima C, Monteiro-Reis S, et al. Downregulation of m(6) A writer complex member METTL14 in bladder urothelial carcinoma suppresses tumor aggressiveness. Mol Oncol. 2022;16:1841\u201356.","journal-title":"Mol Oncol"},{"key":"1434_CR34","doi-asserted-by":"crossref","first-page":"114118","DOI":"10.1016\/j.ejmech.2022.114118","volume":"230","author":"P Xu","year":"2022","unstructured":"Xu P, Ge R. Roles and drug development of METTL3 (methyltransferase-like 3) in anti-tumor therapy. Eur J Med Chem. 2022;230:114118.","journal-title":"Eur J Med Chem"},{"key":"1434_CR35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s11658-024-00545-1","volume":"29","author":"L Lv","year":"2024","unstructured":"Lv L, Wei Q, Zhang J, Dong Y, Shan Z, Chang N, et al. IGF2BP3 prevent HMGB1 mRNA decay in bladder cancer and development. Cell Mol Biol Lett. 2024;29:39.","journal-title":"Cell Mol Biol Lett"},{"key":"1434_CR36","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.7150\/thno.71456","volume":"12","author":"P Liu","year":"2022","unstructured":"Liu P, Fan B, Othmane B, Hu J, Li H, Cui Y, et al. m(6)A-induced lncDBET promotes the malignant progression of bladder cancer through FABP5-mediated lipid metabolism. Theranostics. 2022;12:6291\u2013307.","journal-title":"Theranostics."},{"key":"1434_CR37","volume":"14","author":"W Lin","year":"2023","unstructured":"Lin W, Chen L, Zhang H, Qiu X, Huang Q, Wan F, et al. Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation. Nat Commun. 2023;14:265.","journal-title":"Nat Commun"},{"key":"1434_CR38","doi-asserted-by":"crossref","first-page":"0364","DOI":"10.34133\/research.0364","volume":"7","author":"L Li","year":"2024","unstructured":"Li L, He S, Liao B, Wang M, Lin H, Hu B, et al. Orally administrated hydrogel harnessing intratumoral microbiome and microbiota-related immune responses for potentiated colorectal cancer treatment. Research. 2024;7:0364.","journal-title":"Research"},{"key":"1434_CR39","first-page":"0351","volume":"7","author":"J Wu","year":"2024","unstructured":"Wu J, Liu N, Chen J, Tao Q, Li Q, Li J, et al. The tricarboxylic acid cycle metabolites for cancer: friend or enemy. Research (Wash D C). 2024;7:0351.","journal-title":"Research (Wash D C)"},{"key":"1434_CR40","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1126\/science.add0875","volume":"379","author":"Y Tsukamoto","year":"2023","unstructured":"Tsukamoto Y, Hiono T, Yamada S, Matsuno K, Faist A, Claff T, et al. Inhibition of cellular RNA methyltransferase abrogates influenza virus capping and replication. Science. 2023;379:586\u201391.","journal-title":"Science."},{"key":"1434_CR41","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s43018-020-0056-0","volume":"1","author":"S Suresh","year":"2020","unstructured":"Suresh S, Chen B, Zhu J, Golden RJ, Lu C, Evers BM, et al. eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer. Nat Cancer. 2020;1:533\u201345.","journal-title":"Nat Cancer"},{"key":"1434_CR42","doi-asserted-by":"crossref","first-page":"e2310189","DOI":"10.1002\/adma.202310189","volume":"36","author":"H Yang","year":"2024","unstructured":"Yang H, Yang S, Guo Q, Sheng J, Mao Z. ATP-responsive manganese-based bacterial materials synergistically activate the cGAS-STING pathway for tumor immunotherapy. Adv Mater. 2024;36:e2310189.","journal-title":"Adv Mater"},{"key":"1434_CR43","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41392-023-01703-1","volume":"9","author":"L Wu","year":"2024","unstructured":"Wu L, Du Z, Li L, Qiao L, Zhang S, Yin X, et al. Camouflaging attenuated Salmonella by cryo-shocked macrophages for tumor-targeted therapy. Signal Transduct Target Ther. 2024;9:14.","journal-title":"Signal Transduct Target Ther"},{"key":"1434_CR44","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41585-022-00608-y","volume":"19","author":"YC Lee","year":"2022","unstructured":"Lee YC, Lam HM, Rosser C, Theodorescu D, Parks WC, Chan KS. The dynamic roles of the bladder tumour microenvironment. Nat Rev Urol. 2022;19:515\u201333.","journal-title":"Nat Rev Urol"},{"key":"1434_CR45","doi-asserted-by":"crossref","first-page":"0281","DOI":"10.34133\/research.0281","volume":"6","author":"H Meng","year":"2023","unstructured":"Meng H, Yu Y, Xie E, Wu Q, Yin X, Zhao B, et al. Hepatic HDAC3 regulates systemic iron homeostasis and ferroptosis via the Hippo signaling pathway. Research. 2023;6:0281.","journal-title":"Research"},{"key":"1434_CR46","doi-asserted-by":"crossref","first-page":"0335","DOI":"10.34133\/research.0335","volume":"7","author":"C Xiao","year":"2024","unstructured":"Xiao C, Li J, Hua A, Wang X, Li S, Li Z, et al. Hyperbaric oxygen boosts antitumor efficacy of copper-diethyldithiocarbamate nanoparticles against pancreatic ductal adenocarcinoma by regulating cancer stem cell metabolism. Research. 2024;7:0335.","journal-title":"Research"},{"key":"1434_CR47","doi-asserted-by":"crossref","first-page":"101749","DOI":"10.1016\/j.tranon.2023.101749","volume":"36","author":"J Zhou","year":"2023","unstructured":"Zhou J, Wei Z, Yang C, Jia D, Pan B, Zeng Y, et al. APE1 promotes radiation resistance against radiation-induced pyroptosis by inhibiting the STING pathway in lung adenocarcinoma. Transl Oncol. 2023;36:101749.","journal-title":"Transl Oncol"},{"key":"1434_CR48","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/d41586-021-01943-7","volume":"596","author":"T Vellai","year":"2021","unstructured":"Vellai T. How the amino acid leucine activates the key cell-growth regulator mTOR. Nature. 2021;596:192\u20134.","journal-title":"Nature."},{"key":"1434_CR49","volume":"14","author":"W Fang","year":"2023","unstructured":"Fang W, Jiang L, Zhu Y, Yang S, Qiu H, Cheng J, et al. Methionine restriction constrains lipoylation and activates mitochondria for nitrogenic synthesis of amino acids. Nat Commun. 2023;14:2504.","journal-title":"Nat Commun"},{"key":"1434_CR50","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/s41586-024-07059-y","volume":"626","author":"M Deng","year":"2024","unstructured":"Deng M, Yu J, Blackmond DG. Symmetry breaking and chiral amplification in prebiotic ligation reactions. Nature. 2024;626:1019\u201324.","journal-title":"Nature."},{"key":"1434_CR51","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature08619","volume":"462","author":"RC Grandison","year":"2009","unstructured":"Grandison RC, Piper MD, Partridge L. Amino-acid imbalance explains extension of lifespan by dietary restriction in Drosophila. Nature. 2009;462:1061\u20134.","journal-title":"Nature."},{"key":"1434_CR52","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/1841404a0","volume":"184","author":"M Rechcigl Jr.","year":"1959","unstructured":"Rechcigl M Jr., Berger S, Loosli JK, Williams HH. Effect of \u201camino-acid imbalance\u201d on growth and vitamin A storage in the white rat. Nature. 1959;184:1404.","journal-title":"Nature."},{"key":"1434_CR53","volume":"9","author":"Z Dai","year":"2018","unstructured":"Dai Z, Mentch SJ, Gao X, Nichenametla SN, Locasale JW. Methionine metabolism influences genomic architecture and gene expression through H3K4me3 peak width. Nat Commun. 2018;9:1955.","journal-title":"Nat Commun"},{"key":"1434_CR54","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.cmet.2023.10.002","volume":"35","author":"J Li","year":"2023","unstructured":"Li J, Zheng C, Mai Q, Huang X, Pan W, Lu J, et al. Tyrosine catabolism enhances genotoxic chemotherapy by suppressing translesion DNA synthesis in epithelial ovarian cancer. Cell Metab. 2023;35:2044\u201359.e8.","journal-title":"Cell Metab"},{"key":"1434_CR55","doi-asserted-by":"crossref","first-page":"e13157","DOI":"10.1111\/cpr.13157","volume":"55","author":"J Li","year":"2022","unstructured":"Li J, Chen K, Dong X, Xu Y, Sun Q, Wang H, et al. YTHDF1 promotes mRNA degradation via YTHDF1-AGO2 interaction and phase separation. Cell Prolif. 2022;55:e13157.","journal-title":"Cell Prolif"},{"key":"1434_CR56","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.cell.2020.05.012","volume":"181","author":"S Zaccara","year":"2020","unstructured":"Zaccara S, Jaffrey SR. A unified model for the function of YTHDF proteins in regulating m(6)A-modified mRNA. Cell. 2020;181:1582\u201395.e18.","journal-title":"Cell."}],"container-title":["Cell Death &amp; Differentiation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41418-024-01434-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-024-01434-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-024-01434-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T23:39:01Z","timestamp":1744241941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-024-01434-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1434"],"URL":"https:\/\/doi.org\/10.1038\/s41418-024-01434-y","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,13]]},"assertion":[{"value":"22 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved and overseen by the Ethics Committee of Xiangya Hospital of CSU and the Ethics Committee of the Clinical Research and Animal Testing Ethics Institute at FAH-SYSU. Informed consent was obtained and signed by all participating patients, who agreed to the use of their clinical specimens for medical research. The research methods adhered to the guidelines outlined in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}